2. April 2016 von

Semaglutide Demonstrated Superior Improvements In Glycaemic Control Vs Placebo In Adults With Type 2 Diabetes

Novo Nordisk A/S: Boston (ots/PRNewswire) – For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #OR15-1 Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like …

Comments are closed.